Chemotherapy in Pregnancy

Buekers, Thomas E.; Lallas, Thomas A.

doi:10.1016/s0889-8545(05)70007-3

Cited by 80 publications

(60 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, after the second trimester, Pentheroudakis et al reported that there was no major difference in the incidence rate of malformations or IUGR between infants from normal pregnancies and those from pregnancies in which chemotherapy was administered (8). Additionally, many reports indicate that the use of chemotherapy after the second trimester is relatively safe (1,(7)(8)(9)(10)(11)(12), suggesting that while chemotherapy is not recommended, it can be practically administered.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy Treatment of a Pregnant Woman with Progressive Gastric Cancer

et al. 2015

View full text Add to dashboard Cite

We herein describe a rare case of gastric cancer that was treated with chemotherapy during pregnancy. A woman in her thirty's at 23 weeks of gestation was admitted to the hospital with epigastralgia and left cervical lymph node swelling. She had been previously diagnosed with metastatic adenocarcinoma at another hospital. Findings from a CT scan and esophagogastroduodenoscopy revealed progressive gastric cancer, and the pathology indicated poorly differentiated adenocarcinoma. Chemotherapy was administered at 24 weeks of gestation, without the development of severe toxicity. At 32 weeks of gestation, a healthy baby girl (birth weight 1,442 g, Apgar score 7/8) was delivered by caesarean section. The child continued to show no abnormalities at 12 months after delivery.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy Treatment of a Pregnant Woman with Progressive Gastric Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…increased rate of fetal malformations (8,16,36,37). From the second trimester onwards, growth restriction is the main risk of chemotherapy.…”

Section: Accepted Articlementioning

confidence: 99%

“…disorders affecting future generations (16,37,87,88). Of note, during the time from conception until implantation (6 to 10 days after fertilization), the embryo is undifferentiated, and repair and recovery are possible through multiplication of multipotential cells to replace those that might have been lost.…”

Section: Accepted Articlementioning

confidence: 99%

See 1 more Smart Citation

Acute myeloid leukemia in the pregnant patient

Thomas

2015

European J of Haematology

View full text Add to dashboard Cite

Although acute myeloid leukemia (AML) mostly occurs in older patients, it could be seen in women of childbearing age. It is therefore not surprising that in some patients the management of AML will be complicated by a coexistent pregnancy. However, the association of leukemia and pregnancy is uncommon. Its incidence is estimated to be 1 in 75,000 to 100,000 pregnancies. During pregnancy, most leukemias are acute: two thirds are myeloid and one third are lymphoblastic. There is no standard approach for this clinical dilemma, in part because of Accepted ArticleThis article is protected by copyright. All rights reserved.variables such as the type of AML, the seriousness of the symptoms, and the patient's personal beliefs. In many cases, the diagnostic work up has to be altered because of the pregnancy, and often available treatments have varying risks to the fetus. While chemotherapy is reported to have some risks during the first trimester, it is admitted that it can be administered safely during the second and the third trimesters.

show abstract

“…Pregnancy does not appear to affect the course of CML, there is still a risk of leukostasis as well as risk of placental insufficiency with consequent below normal fetal birth weight, increased prematurity, and increased mortality if CML left untreated for the duration of pregnancy. 2 Imatinib mesylate (ST1571, Gleevec, Norvatis) entered clinical trials in 1998 and has since been shown to induce dramatic hematologic and cytogenetic response in CML. 3 Imatinib has been found to be antiangiogenic in animal models.…”

Section: Introductionmentioning

confidence: 99%